NeoGenomics Inc (NEO)
Healthcare
Diagnostics & Research
15.30 $
Closing price · As of: 31. Jul 2026
🔔 Watch stock
Stock Watch
Stock Watch will tell you what changes at NeoGenomics Inc.
Later $1 a month per stock — signing up is free, and you'll be the first to know when it launches.
Basics
Market Cap
The value of the entire company on the market: share price times total shares outstanding.
2.0$B
Shares Outstanding
Total number of shares issued. Price times share count gives market cap.
130Mio.
Float
Share of stock freely tradable on the market — not locked up in the hands of founders, insiders, or major shareholders.
90.8%
Beta
Volatility versus the overall market: 1 = moves like the market, 2 = twice as much, under 1 = calmer than the market.
1.7
Performance
Perf. 1M
Price performance over the last month.
39.80%
Perf. 3M
Price performance over the last 3 months.
98.20%
Perf. 6M
Price performance over the last 6 months.
15.90%
YTD Performance (%)
Price performance since the start of the year (Year to Date).
-2.50%
52-Week-High Distance
How far the price sits below its highest point over the last 52 weeks. 0% means the stock is at its year high.
-1.1%
Valuation
P/E
Price-to-earnings ratio: how many years of profit does the stock cost? The lower, the cheaper the valuation. No earnings means no P/E.
–
Forward P/E
P/E based on expected earnings for the next 12 months instead of past earnings — analysts' bet on the future.
222.2
PEG
P/E divided by expected earnings growth: puts valuation in relation to growth. Around 1 is considered fair, well above that is pricey.
2.1
P/B
Price-to-book ratio: market value relative to book equity.
2.4
P/S
Price-to-sales ratio: market value divided by annual sales. Important for companies that aren't (yet) profitable.
2.7
EV/EBITDA
Enterprise value including debt (EV) relative to operating profit before depreciation and amortization (EBITDA) — more comparable than P/E because debt counts too. Extreme values arise when EBITDA is near zero.
945.4
Price/FCF
Market value divided by free cash flow: how many years of freely available cash does the stock cost? More honest than P/E because cash flow is harder to dress up.
–
Profitability
Gross Margin
Gross margin: what's left of sales after only direct production costs are deducted — the product's pricing power.
43.1%
EBIT Margin
EBIT margin: operating profit as a percentage of sales — the earning power of the core business before interest and taxes.
-9.3%
Net Margin
Net margin: what's left of sales as profit after ALL costs, interest, and taxes.
-13.3%
Return on Equity
Return on equity: how much profit does the company generate per year on shareholders' equity?
-11.6%
Return on Assets
Return on assets: how much profit the company generates from its total assets (equity and debt combined).
-2.6%
Balance Sheet & Safety
Equity Ratio
Equity ratio: equity as a share of total assets. The higher, the more resilient the balance sheet.
61.6%
Debt/Equity
Leverage ratio: financial debt divided by equity. Under 1 is generally seen as solid; negative values mean negative equity.
0.5
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
4.75
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
6 out of 9
Growth
Sales Growth Last Quarter
Sales growth in the most recently reported quarter versus the same quarter a year ago (YoY).
11.10%
EPS Growth Last Quarter
Growth in earnings per share in the most recently reported quarter versus the same quarter a year ago (YoY).
130.60%
Sales Growth (Year)
Sales growth in the last fiscal year versus the year before.
10.11%
Forward Sales Growth
Sales growth analysts expect over the next 12 months — an estimate, not a guarantee.
10.03%
Forward EPS Growth
Earnings-per-share growth analysts expect over the next 12 months — an estimate, not a guarantee.
102.50%
Quality & Screener
Stage
Weinstein phases 1 through 4: 1 = basing, 2 = uptrend (the only buy phase), 3 = topping, 4 = downtrend. Measured against the 30-week line.
3
RS Rating
Relative strength from 1 to 99: an RS of 95 means the stock has outperformed 95% of all stocks.
78
EPS Rating
Earnings growth rating from 1 to 99 versus all stocks — high values mean above-average earnings growth.
88
Piotroski
Balance-sheet health check by Joseph Piotroski: 9 yes/no criteria on profit, cash flow, leverage, and efficiency. 7+ is very solid, under 3 is a red flag.
6 out of 9
Fundamental Rating
Our own Fundamental Rating: 0 to 100 points with an A+ to F grade. 50 points is the average across the universe, 100 the best possible score. It scores growth, earnings surprises, analyst estimates, margins, cash flow, and balance-sheet safety — every stock percentile-ranked against all others. Grades: A+ from 95, A from 75, B from 55, C from 45, D from 25, E from 5, F below.
C (52 out of 100)
Altman Z″
Edward Altman's bankruptcy early-warning score. We use the Z″ variant, built from four balance-sheet ratios — it is designed for service companies and non-manufacturers and uses book value instead of market value. On that scale: below 1.1 = danger zone, 2.6 and up = safe zone, in between a grey area. Because the classic Altman Z is calculated differently, the two numbers are not directly comparable. The formula does not fit banks, insurers, or real-estate stocks.
4.75
AI Rating
–Not yet rated — we only show a category once an SEC-backed file with at least two cited passages is available. How the Rating Is Built
Quarterly Figures
| Quarter | EPS (Earnings Per Share) | EPS YoY (%) | Sales ($M) | Sales YoY (%) | Net Margin (%) | OCF ($M) | FCF ($M) |
|---|---|---|---|---|---|---|---|
| 2024: Q4 | -0.60 | – | 172 | 10.60 | -8.90 | 10 | -2 |
| 2025: Q1 | -1.02 | – | 168 | 7.50 | -15.40 | -25 | -30 |
| 2025: Q2 | -1.76 | – | 181 | 10.20 | -24.90 | 20 | 14 |
| 2025: Q3 | -1.06 | – | 188 | 11.90 | -14.40 | 9 | 1 |
| 2025: Q4 | -0.38 | – | 190 | 10.60 | -5.20 | 1 | -7 |
| 2026: Q1 | -0.66 | – | 187 | 11.10 | -9.20 | -8 | -13 |
What Do These Terms Mean?
- EPS (Earnings Per Share):
- Quarterly profit divided by the total share count — how much of the profit works out to a single share.
- YoY (Year over Year):
- Change versus the same quarter a year ago — this is how you compare without seasonal distortion (e.g. the holiday shopping season).
- Sales:
- All revenue for the quarter, before any costs are deducted — the top line of the income statement.
- Net Margin:
- What percentage of sales is left over as profit in the end. Negative means the company is posting a loss.
- OCF (Operating Cash Flow):
- The cash that actually flows into the till from the core business during the quarter — harder to dress up than book profit.
- FCF (Free Cash Flow):
- Operating cash flow minus capital expenditures — the money that's genuinely free to use, say for paying down debt, buybacks, or dividends.
About the Company
NeoGenomics, Inc. betreibt ein Netzwerk krebsspezialisierter Testlabore in den USA und Großbritannien.
| Employees | 2,500 |
|---|---|
| Headquarters | Fort Myers, FL |
| Website | neogenomics.com |
| IPO Date | 2. Nov 1999 |
| Next Earnings | 4. Aug 2026 |
Management
| Name | Title | Birth Year |
|---|---|---|
| Anthony P. Zook | CEO & Director | 1961 |
| Warren Stone | President & COO | 1973 |
| Elizabeth A. Floegel | Chief Digital & Information Officer | 1976 |
| Alicia C. Olivo | Executive VP of Business Development, General Counsel & Corporate Secretary | 1984 |
| Gary Passman | Chief People & Culture Officer | – |
| Abhishek Jain | Executive VP & CFO | 1976 |
| Gregory D. Aunan | Senior VP & Chief Accounting Officer | 1969 |
| Kendra Sweeney | Vice President of Investor Relations & Communications | – |
| Clarence Cooper Esq. | Vice President of Compliance & Privacy | – |
| Kareem M. Saad | Head of Strategy, Business Development & Transformation | 1979 |
Executives per the latest required filings; titles kept in their original language. Source: fundamental data.
Chart
Interactive price chart (TradingView).
Data as of: July 31, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.